Latest Migraine & Headache Research
MigraineMind provides concise summaries, key learning points and links to the original scientific publications behind recently published migraine and headache research. Learn about MigraineMind or read how the research summaries are made.
Browse migraine research by topic
Explore focused collections that currently meet MigraineMind’s five-paper quality threshold.
-
Migraine
Migraine affects about 12% of people worldwide. Chronic migraine impacts 1% to 2% of the global population. Approximately 2.5% of individuals with episodic migraine develop chronic migraine. There are several risk…
-
Migraine and the trigeminovascular system—40 years and counting
The causes of migraine headaches puzzled researchers throughout much of the 20th century. In 1979, a significant hypothesis emerged, highlighting the trigeminal nerve's role. This idea transformed the migraine…
-
The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice
This position statement offers healthcare professionals updated guidance on migraine treatments. It focuses on integrating new preventive and acute therapies for adults. Recent developments in technologies and…
-
Galcanezumab in chronic migraine
This study evaluated galcanezumab's effectiveness for preventing chronic migraines. Galcanezumab is a humanized monoclonal antibody targeting calcitonin gene-related peptide. It was tested in a phase 3, randomized…
-
Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
Headaches are a significant global health issue, particularly migraine and tension-type headache. In 2016, nearly three billion people experienced these headaches worldwide. Of those, 1.89 billion had tension-type…
-
Evaluation of Galcanezumab for the Prevention of Episodic Migraine
Migraine is a debilitating condition marked by severe headache attacks. Current treatments often reduce migraine frequency but can cause adverse effects. This study assessed galcanezumab's efficacy compared to…
-
CGRP as the target of new migraine therapies — successful translation from bench to clinic
Migraine treatment is entering a transformative era focused on CGRP-targeted therapies. These drugs target calcitonin gene-related peptide or its receptor, enhancing migraine management. Approval for several of these…
-
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
Erenumab is a monoclonal antibody that targets the calcitonin gene-related peptide receptor. This study evaluated erenumab's effectiveness for preventing episodic migraines. Five hundred seventy-seven adults…
-
The pathophysiology of migraine: implications for clinical management
Recent research shows that migraine understanding is evolving quickly. This condition is now seen as a complex disorder affecting nervous system function. It is not just a vascular headache anymore. New studies…
-
A Controlled Trial of Erenumab for Episodic Migraine
In this study, researchers evaluated erenumab for preventing episodic migraine. Erenumab is a monoclonal antibody that inhibits a specific receptor. Patients received a monthly injection of either 70 mg, 140 mg, or…
-
Fremanezumab for the Preventive Treatment of Chronic Migraine
Fremanezumab is a monoclonal antibody aimed at preventing chronic migraines. This study compared its effectiveness to placebo in a phase 3 trial. Patients with chronic migraines received one of three treatments. They…
-
Stem Cells in the Treatment of Refractory Chronic Migraines
Autologous adipose-derived stromal vascular fraction (SVF) shows promise for treating migraines. This treatment is rich in mesenchymal stromal cells. It may target neurogenic inflammation in migraine pathogenesis…
-
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
The study explored erenumab's safety and efficacy in chronic migraine patients. Researchers conducted a phase 2, randomized, double-blind trial across 69 centers in North America and Europe. Participants were adults…
-
The role of calcitonin gene–related peptide in peripheral and central pain mechanisms including migraine
Calcitonin gene-related peptide, or CGRP, is a vital 37-amino acid peptide. It is mainly found in sensory fibers from the dorsal root and trigeminal ganglia. CGRP also exists in the central nervous system. This…
-
Pathophysiology of Migraine: A Disorder of Sensory Processing
Migraine affects over one billion people globally and is highly disabling. Its pathophysiology has evolved significantly from ancient theories to modern neurological understanding. Researchers consider three main…
-
Sex differences in the epidemiology, clinical features, and pathophysiology of migraine
Migraine affects women two to three times more than men. Women experience longer attacks and increased headache recurrence. They also report greater disability and longer recovery times. Comorbidities, such as…
-
Chronic migraine: risk factors, mechanisms and treatment
Chronic migraine significantly impacts patients' lives, affecting their quality and socioeconomic functioning. It affects 1-2% of the general population and 8% of migraine patients. Chronic migraine usually develops…
-
Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine
Migraine affects about 14% of people globally and is quite debilitating. Its underlying causes remain unclear, sparking debate about vascular versus neuronal dysfunction. Previous studies found 13 loci linked to…
-
The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks
Recent research explored brain activity during migraines using advanced imaging techniques. Specifically, positron emission tomography and functional magnetic resonance imaging were utilized. The study identified a…
-
Migraine: Multiple Processes, Complex Pathophysiology
Migraine is a common, hereditary neurovascular headache disorder affecting many individuals. It often begins in childhood, increasing from a few times yearly to weekly in adulthood, especially in females. Migraine…